Citations (57)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (13)
Andréa Name Colado Simão, Marcell Alysson Batisti Lozovoy & Isaias Dichi. (2012) The uric acid metabolism pathway as a therapeutic target in hyperuricemia related to metabolic syndrome. Expert Opinion on Therapeutic Targets 16:12, pages 1175-1187.
Read now
Read now
Niki Katsiki, Apostolos I. Hatzitolios & Dimitri P. Mikhailidis. (2011) Naltrexone sustained-release (SR) + bupropion SR combination therapy for the treatment of obesity: ‘A new kid on the block’?. Annals of Medicine 43:4, pages 249-258.
Read now
Read now
Niki Katsiki, Dimitri P Mikhailidis, Anna Gotzamani-Psarrakou, John G Yovos & Dimitrios Karamitsos. (2011) Effect of various treatments on leptin, adiponectin, ghrelin and neuropeptide Y in patients with type 2 diabetes mellitus. Expert Opinion on Therapeutic Targets 15:4, pages 401-420.
Read now
Read now
Konstantinos Tziomalos, Gerasimos E Krassas & Themistoklis Tzotzas. (2009) The use of sibutramine in the management of obesity and related disorders: An update. Vascular Health and Risk Management 5, pages 441-452.
Read now
Read now
M Florentin, EN Liberopoulos, TD Filippatos, C Kostara, A Tselepis, DP Mikhailidis & M Elisaf. (2008) Effect of rimonabant, micronised fenofibrate and their combination on cardiometabolic risk factors in overweight/obese patients: a pilot study. Expert Opinion on Pharmacotherapy 9:16, pages 2741-2750.
Read now
Read now
E Nakou, TD Filippatos, EN Liberopoulos, AD Tselepis, DN Kiortsis, DP Mikhailidis & MS Elisaf. (2008) Effects of sibutramine plus verapamil sustained release/trandolapril combination on blood pressure and metabolic variables in obese hypertensive patients. Expert Opinion on Pharmacotherapy 9:10, pages 1629-1639.
Read now
Read now
E. S. Nakou, T. D. Filippatos, M. Georgoula, D. N. Kiortsis, A. D. Tselepis, D. P. Mikhailidis & M. S. Elisaf. (2008) The effect of orlistat and ezetimibe, alone or in combination, on serum LDL and small dense LDL cholesterol levels in overweight and obese patients with hypercholesterolaemia. Current Medical Research and Opinion 24:7, pages 1919-1929.
Read now
Read now
Alessandro Federico, Marco Niosi, Camillo Del Vecchio Blanco & Carmela Loguercio. (2008) Emerging drugs for non-alcoholic fatty liver disease. Expert Opinion on Emerging Drugs 13:1, pages 145-158.
Read now
Read now
Giuseppe Calamita & Piero Portincasa. (2007) Present and future therapeutic strategies in non-alcoholic fatty liver disease. Expert Opinion on Therapeutic Targets 11:9, pages 1231-1249.
Read now
Read now
H. Farshchi, A. Rane, A. Love & R. L. Kennedy. (2007) Diet and nutrition in polycystic ovary syndrome (PCOS): Pointers for nutritional management. Journal of Obstetrics and Gynaecology 27:8, pages 762-773.
Read now
Read now
Harold Bays, Lawrence Blonde & Robert Rosenson. (2006) Adiposopathy: how do diet, exercise and weight loss drug therapies improve metabolic disease in overweight patients?. Expert Review of Cardiovascular Therapy 4:6, pages 871-895.
Read now
Read now
T. D. Filippatos, D. N. Kiortsis, E. N. Liberopoulos, M. Georgoula, D. P. Mikhailidis & M. S. Elisaf. (2005) Effect of orlistat, micronised fenofibrate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome: the FenOrli study. Current Medical Research and Opinion 21:12, pages 1997-2006.
Read now
Read now
Sheila A Doggrell. (2005) Is the cannabinoid CB1 receptor antagonist rimonabant advancing the treatment of obesity?. Expert Opinion on Pharmacotherapy 6:12, pages 2141-2144.
Read now
Read now
Articles from other publishers (44)
Dan Osei Mensah Bonsu, Constance Afoakwah & Maria de la Paz Aguilar-Caballos. (2021) Counterfeit formulations: analytical perspective on anorectics. Forensic Toxicology 39:1, pages 1-25.
Crossref
Crossref
Georgios A. Christou, Niki Katsiki, John Blundell, Gema Fruhbeck & Dimitrios N. Kiortsis. (2019) Semaglutide as a promising antiobesity drug. Obesity Reviews 20:6, pages 805-815.
Crossref
Crossref
Alexandru Robert Vlad, Gabriel Hancu, Hajnal Kelemen, Diana Ciurcă & Amelia Tero-Vescan. (2017) Analytical Methodologies for the Stereoselective Determination of Sibutramine: An Overview. Acta Medica Marisiensis 63:2, pages 52-55.
Crossref
Crossref
Nele Plock, Leon Bax, Douglas Lee, Deborah DeManno, Gezim Lahu & Marc Pfister. (2017) Exploratory Literature Meta-Analysis to Characterize the Relationship Between Early and Longer Term Body Weight Loss for Antiobesity Compounds. The Journal of Clinical Pharmacology 57:1, pages 52-63.
Crossref
Crossref
Tat'yana Ivanovna Romantsova. (2015) Sibutramine: efficacy and safety of prescribing in routine clinical practice. Obesity and metabolism 12:3, pages 18-24.
Crossref
Crossref
Niki Katsiki, Dimitri P. Mikhailidis & Devaki R. Nair. (2014) The effects of antiepileptic drugs on vascular risk factors: A narrative review. Seizure 23:9, pages 677-684.
Crossref
Crossref
Niki Katsiki, Asterios Karagiannis, Vasilios G. Athyros & Dimitri P. Mikhailidis. (2013) Hyperuricaemia. Journal of Cardiovascular Medicine 14:6, pages 397-402.
Crossref
Crossref
Helle Skak-Nielsen, Christian Torp-Pedersen, Nick Finer, Ian D. Caterson, Luc Van Gaal, W. Philip T James, Aldo Pietro Maggioni, Arya M. Sharma, Walmir Coutinho & Charlotte Andersson. (2013) Uric Acid as a Risk Factor for Cardiovascular Disease and Mortality in Overweight/Obese Individuals. PLoS ONE 8:3, pages e59121.
Crossref
Crossref
Changgui Li, Ming-Chia Hsieh & Shun-Jen Chang. (2013) Metabolic syndrome, diabetes, and hyperuricemia. Current Opinion in Rheumatology 25:2, pages 210-216.
Crossref
Crossref
Shalini Dalal, David Hui, Luc Bidaut, Kristen Lem, Egidio Del Fabbro, Christopher Crane, Cielito C. Reyes-Gibby, Deepak Bedi & Eduardo Bruera. (2012) Relationships Among Body Mass Index, Longitudinal Body Composition Alterations, and Survival in Patients With Locally Advanced Pancreatic Cancer Receiving Chemoradiation: A Pilot Study. Journal of Pain and Symptom Management 44:2, pages 181-191.
Crossref
Crossref
Saleh Binsaleh. (2013) Sibutramine for the Treatment of Recurrent High‐Flow Priapism. Journal of Andrology 33:4, pages 566-569.
Crossref
Crossref
Niki Katsiki, John G. Yovos, Anna Gotzamani-Psarrakou & Dimitrios T. Karamitsos. (2011) Adipokines and Vascular Risk in Type 2 Diabetes Mellitus. Angiology 62:8, pages 601-604.
Crossref
Crossref
Morgan Downey, Christopher Still & Arya M. Sharma. (2011) Is there a path for approval of an antiobesity drug. Current Opinion in Endocrinology, Diabetes & Obesity 18:5, pages 321-327.
Crossref
Crossref
André J. Scheen. (2011) Sibutramine on Cardiovascular Outcome. Diabetes Care 34:Supplement_2, pages S114-S119.
Crossref
Crossref
A.J. Scheen. (2010) Cardiovascular Risk-Benefit Profile of Sibutramine. American Journal Cardiovascular Drugs 10:5, pages 321-334.
Crossref
Crossref
Ramazan Sari, Esin Eray, Sabahat Ozdem, Halide Akbas & Erkan Coban. (2009) Comparison of the effects of sibutramine versus sibutramine plus metformin in obese women. Clinical and Experimental Medicine 10:3, pages 179-184.
Crossref
Crossref
Stergios A. Polyzos, Jannis Kountouras, Christos Zavos & Eleni Tsiaousi. (2010) The role of adiponectin in the pathogenesis and treatment of non‐alcoholic fatty liver disease. Diabetes, Obesity and Metabolism 12:5, pages 365-383.
Crossref
Crossref
Theodosios D Filippatos. (2010) Combination drug treatment in obese diabetic patients. World Journal of Diabetes 1:1, pages 8.
Crossref
Crossref
Souzana Choussein, Angeliki A. Makri, Constantinos C. Frangos, Eleni Th. Petridou & Stella S. Daskalopoulou. (2009) Effect of antiobesity medications in patients with type 2 diabetes mellitus. Diabetes, Obesity and Metabolism 11:7, pages 641-664.
Crossref
Crossref
Walmir Coutinho. (2009) The first decade of sibutramine and orlistat: a reappraisal of their expanding roles in the treatment of obesity and associated conditions. Arquivos Brasileiros de Endocrinologia & Metabologia 53:2, pages 262-270.
Crossref
Crossref
Weidong Xie, Yaou Zhang, Naili Wang, Hua Zhou, Lijun Du, Xiaohui Ma, Xiaojun Shi & Guoping Cai. (2008) Novel effects of macrostemonoside A, a compound from Allium macrostemon Bung, on hyperglycemia, hyperlipidemia, and visceral obesity in high-fat diet-fed C57BL/6 mice. European Journal of Pharmacology 599:1-3, pages 159-165.
Crossref
Crossref
Hernani Pinto de Lemos Júnior, Álvaro Nagib Atallah & André Luis Alves de Lemos. (2008) Can sibutramine alter systemic blood pressure in obese patients? Systematic review and meta-analysis. Sao Paulo Medical Journal 126:6, pages 342-346.
Crossref
Crossref
M. Florentin, E. N. Liberopoulos & M. S. Elisaf. (2008) Sibutramine-associated adverse effects: a practical guide for its safe use. Obesity Reviews 9:4, pages 378-387.
Crossref
Crossref
Giovanni de Simone & Gianpaolo D'Addeo. (2008) Sibutramine: Balancing weight loss benefit and possible cardiovascular risk. Nutrition, Metabolism and Cardiovascular Diseases 18:5, pages 337-341.
Crossref
Crossref
María D. Ballesteros-Pomar & Miguel León-Sanz. (2008) Nutrition in the metabolic syndrome: Pharmacological treatment. e-SPEN, the European e-Journal of Clinical Nutrition and Metabolism 3:3, pages e108-e116.
Crossref
Crossref
M.C. Iglesias-Osma, M.A. Torres, M.J. García-Barrado & J. Moratinos. (2008) Adipocitocinas: implicaciones en el pronóstico y tratamiento farmacológico de patología cardiovascular. Revista Clínica Española 208:5, pages 239-246.
Crossref
Crossref
Stefan Engeli, Karsten Heusser, Jürgen Janke, Kerstin Gorzelniak, Sándor Bátkai, Pál Pacher, Judith Harvey‐White, Friedrich C. Luft & Jens Jordan. (2012) Peripheral Endocannabinoid System Activity in Patients Treated With Sibutramine. Obesity 16:5, pages 1135-1137.
Crossref
Crossref
Åsa Lindholm, Marie Bixo, Inger Björn, Pål Wölner-Hanssen, Mats Eliasson, Anders Larsson, Owe Johnson & Inger Sundström Poromaa. (2008) Effect of sibutramine on weight reduction in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. Fertility and Sterility 89:5, pages 1221-1228.
Crossref
Crossref
D.N. Kiortsis, S. Tsouli, T.D. Filippatos, S. Konitsiotis & M.S. Elisaf. (2008) Effects of sibutramine and orlistat on mood in obese and overweight subjects: A randomised study. Nutrition, Metabolism and Cardiovascular Diseases 18:3, pages 207-210.
Crossref
Crossref
Miguel A Rubio, Manuel Gargallo, Ana Isabel Millán & Basilio Moreno. (2007) Drugs in the treatment of obesity: sibutramine, orlistat and rimonabant. Public Health Nutrition 10:10A, pages 1200-1205.
Crossref
Crossref
T.D. Filippatos, I.F. Gazi, E.N. Liberopoulos, V.G. Athyros, M.S. Elisaf, A.D. Tselepis & D.N. Kiortsis. (2007) The effect of orlistat and fenofibrate, alone or in combination, on small dense LDL and lipoprotein-associated phospholipase A2 in obese patients with metabolic syndrome. Atherosclerosis 193:2, pages 428-437.
Crossref
Crossref
Zafar H Israili, Badiâa Lyoussi, Rafael Hernández-Hernández & Manuel Velasco. (2007) Metabolic Syndrome: Treatment of Hypertensive Patients. American Journal of Therapeutics 14:4, pages 386-402.
Crossref
Crossref
S.A. Ritchie & J.M.C. Connell. (2007) The link between abdominal obesity, metabolic syndrome and cardiovascular disease. Nutrition, Metabolism and Cardiovascular Diseases 17:4, pages 319-326.
Crossref
Crossref
Pilar Orozco López. (2007) ¿Cuándo estaría indicado el tratamiento con sibutramina y durante cuánto tiempo?. FMC - Formación Médica Continuada en Atención Primaria 14:5, pages 281-282.
Crossref
Crossref
Jin Li, Brian S. Bronk, John P. Dirlam, Alan E. Blize, Peter Bertinato, Burton H. Jaynes, Anne Hickman, Christine Miskell, Usha A. Pillai, Jay S. Tibbitts, Michelle L. Haven, Nicole L. Kolosko, Chris J. Barry & Tara B. Manion. (2007) In vitro and in vivo profile of 5-[(4′-trifluoromethyl-biphenyl-2-carbonyl)-amino]-1H-indole-2-carboxylic acid benzylmethyl carbamoylamide (dirlotapide), a novel potent MTP inhibitor for obesity. Bioorganic & Medicinal Chemistry Letters 17:7, pages 1996-1999.
Crossref
Crossref
B J Yee, C L Phillips, D Banerjee, I Caterson, J A Hedner & R R Grunstein. (2006) The effect of sibutramine-assisted weight loss in men with obstructive sleep apnoea. International Journal of Obesity 31:1, pages 161-168.
Crossref
Crossref
Sofia G. Tsouli, Evangelos N. Liberopoulos, Dimitri P. Mikhailidis, Vasilios G. Athyros & Moses S. Elisaf. (2006) Elevated serum uric acid levels in metabolic syndrome: an active component or an innocent bystander?. Metabolism 55:10, pages 1293-1301.
Crossref
Crossref
Behzad Molavi, Neda Rasouli & Philip A Kern. (2006) The prevention and treatment of metabolic syndrome and high-risk obesity. Current Opinion in Cardiology 21:5, pages 479-485.
Crossref
Crossref
Titus Kaletta & Michael O. Hengartner. (2006) Finding function in novel targets: C. elegans as a model organism. Nature Reviews Drug Discovery 5:5, pages 387-399.
Crossref
Crossref
AH Barnett & S Bellary. (2006) Novel metabolic drugs for the management of type 2 diabetes. Practical Diabetes International 23:3, pages 129-134.
Crossref
Crossref
Harold Bays & Carlos A. Dujovne. (2006) Adiposopathy is a more rational treatment target for metabolic disease than obesity alone. Current Atherosclerosis Reports 8:2, pages 144-156.
Crossref
Crossref
Jan O. Nehlin. 2006. Prevention and Treatment of Age-related Diseases. Prevention and Treatment of Age-related Diseases
133
157
.
E. N. Liberopoulos, D. P. Mikhailidis & M. S. Elisaf. (2005) Diagnosis and management of the metabolic syndrome in obesity. Obesity Reviews 6:4, pages 283-296.
Crossref
Crossref
R. L. Kennedy & E. Y. H. Khoo. (2005) New options for drug treatment of obesity in patients with Type 2 diabetes. Diabetic Medicine 22:s4, pages 23-26.
Crossref
Crossref